The content of functional hematopoietic progenitor cells (HPCs) in a cell therapy product may be negatively affected by time lapses between product collection and infusion, or as a result of delays between processing and cryopreservation or between thawing and infusion. There are many different practices in current use that are designed to maintain viable HPCs, such as overnight refrigeration prior to processing and cryopreservation, cooling cells on ice prior to and during the addition of the cryoprotectant, and post-thaw washing. In addition to HPC products, novel cell therapy products may require development studies and validations to define acceptable in-process storage conditions. This session will focus on the effects of time and temperature on product quality for multiple cell therapy product types at various time points between collection and infusion.

*CT Program

You will have the ability to purchase CD-ROMs of this Audioconference 2 weeks after the session has been presented. For any questions, please contact MultiviewMediaSupport@multiview.com.